Empowering Medical Aesthetic Clinics, Practitioners, and Patients Xeomin® as a Botox® Alternative: 2026 Guide
Last updated: September 2026
Xeomin® (incobotulinumtoxinA) is the product most injectors reach for when a patient asks whether there is an alternative to Botox®. It is made by Merz Aesthetics, it has been on the U.S. market since 2011, and it is one of six botulinum toxin type A products approved by the Food and Drug Administration.
This guide covers the product itself: what Xeomin® is, what it is actually approved to treat in 2026, how it is dosed area by area, how it is stored, and what its label says about safety. It closes with the other question patients mean when they ask for an alternative — the options that are not a neurotoxin at all. For the head-to-head numbers on onset, duration and cost per unit across products, see our Xeomin® vs Botox® vs Dysport® comparison.
Key Takeaways
- Xeomin® is approved for three upper facial areas — glabellar lines, horizontal forehead lines and lateral canthal lines — and since July 23, 2024 it is the first and only U.S. neurotoxin approved to treat all three in the same session, up to 64 Units.
- It is free of complexing proteins, not free of additives. Each vial still contains human albumin 1 mg and sucrose 4.7 mg.
- No refrigeration before use. Unopened vials sit at or below 25°C with a 36-month shelf life; once reconstituted, 2–8°C and used within 24 hours.
- Onset is a median of two to seven days and retreatment is no more often than every three months — the "lasts five to six months" claim is not supported by the Xeomin® label.
- Non-toxin options treat a different problem. Fillers, energy devices and retinoids address static lines and skin quality; none of them relaxes the muscle creating a dynamic line.
What Xeomin® Is
Xeomin® is incobotulinumtoxinA, a purified botulinum toxin type A. Like every product in this class it works by blocking acetylcholine release at the neuromuscular junction, which relaxes the muscle that creates a dynamic line.
What separates Xeomin® from the others is what has been taken out of it. In most botulinum toxin products the active 150 kDa neurotoxin travels inside a cluster of accessory proteins the bacterium produces alongside it. Merz removes those. Think of the neurotoxin as a book: the other products ship it in a box with packing material, and Xeomin® ships the book on its own.
That is worth stating precisely, because a great deal of published material gets it wrong. Xeomin® is not additive-free. Each vial contains human albumin 1 mg and sucrose 4.7 mg as excipients — the albumin is prominent enough that the label carries its own warning about human albumin and the theoretical transmission of viral diseases. The accurate claim is that Xeomin® carries no complexing proteins, not that it carries nothing but toxin.
25°CUnopened storage, no fridge
36 moUnopened shelf life
64 UMax for all three upper areas
0.3%Neutralizing antibodies in trials
What Xeomin® Is FDA-Approved to Treat in 2026
This is where most older articles about Xeomin® are out of date. For years the aesthetic label covered glabellar lines only, which meant crow's feet and forehead treatment sat off-label. That changed on July 23, 2024, when the FDA approved Xeomin® for moderate to severe lateral canthal lines and horizontal forehead lines as well — and, uniquely, for treating all three upper facial areas in a single session. The approval rested on phase 3 placebo-controlled studies in 730 adults, with all treatment-related adverse events mild to moderate and no treatment-related serious adverse events, and continued efficacy across 14 months of repeat treatment cycles.
If you plan treatment across several areas in one visit, that approval changes the consent conversation as much as the technique — our guide to full-face Botox® injection strategy covers sequencing and unit planning across the face.
The current label, revised June 2026, covers both aesthetic and therapeutic uses:
| Indication | Population | Category |
|---|
| Moderate to severe glabellar lines | Adults | Aesthetic |
|---|
| Moderate to severe horizontal forehead lines | Adults | Aesthetic |
|---|
| Moderate to severe lateral canthal lines | Adults | Aesthetic |
|---|
| Chronic sialorrhea | Patients 2 years and older | Therapeutic |
|---|
| Upper limb spasticity | Patients 2 years and older | Therapeutic |
|---|
| Cervical dystonia | Adults | Therapeutic |
|---|
| Blepharospasm | Adults | Therapeutic |
|---|
Xeomin® Dosing by Area
Every approved aesthetic site takes the same four Units per injection point, which makes the arithmetic unusually easy to hold in your head. Where those points sit is the part that takes training — if you are still building that map, start with essential anatomy for Botox® injection sites.
| Treatment area | Units per site | Sites | Total dose |
|---|
| Glabellar lines | 4 Units | 5 | 20 Units |
|---|
| Horizontal forehead lines | 4 Units | 5 | 20 Units |
|---|
| Lateral canthal lines | 4 Units | 3 per side (6 total) | 24 Units |
|---|
| All three areas, same session | 4 Units | 16 | 64 Units maximum |
|---|
The median onset of effect occurs within two to seven days of injection, and treatment should be repeated no more frequently than every three months. One caution that applies every time: the Xeomin® label states that its potency Units cannot be compared to or converted into Units of any other botulinum toxin preparation. Plan the dose from the label of the product in your hand, never by converting from another.
Comparing products? Onset, duration, cost per unit and the dosing differences across all six approved neurotoxins are covered in detail in the full product comparison.
Storage and Handling
This is Xeomin®'s most practical advantage and the one most often stated too loosely. Unopened vials are stored at or below 25°C — ordinary room temperature — and refrigeration is not required, with a 36-month shelf life. Once reconstituted, Xeomin® behaves like the rest of the class: refrigerate at 2–8°C and use within 24 hours.
For a mobile injector, a satellite treatment room, or a practice that would rather not tie inventory to a single fridge and its temperature log, that is a real operational difference rather than a marketing line. Xeomin® is supplied in 50, 100 and 200 Unit vials, which gives some flexibility in matching vial size to a day's booked treatment volume and reducing waste.
Safety: What the Label Actually Says
Xeomin® carries the same boxed warning as every botulinum toxin product: distant spread of toxin effect. Postmarketing reports indicate effects may spread from the injection area to produce symptoms consistent with botulinum toxin effects, and swallowing and breathing difficulties can be life-threatening, with reports of death. At aesthetic doses this is rare, but it is the most serious item on the label and deserves to be named as such in consent rather than buried in a list.
The label lists exactly two contraindications: known hypersensitivity to botulinum neurotoxin type A or to any of the excipients, and infection at the proposed injection site. Pregnancy is not among them — it is handled under Pregnancy, where animal studies showed embryotoxicity in rats and increased abortions in rabbits at doses above the maximum recommended human dose, and the guidance is to use only if the potential benefit justifies the risk to the fetus. There are no lactation data. Most aesthetic practices defer elective treatment in both situations.
Warnings and precautions cover spread of toxin effect, lack of unit equivalency between products, hypersensitivity reactions, dysphagia and breathing difficulties, corneal exposure and ulceration, risk of ptosis in patients treated for glabellar lines, human albumin and viral transmission, and pre-existing conditions at the injection site. Patients with neuromuscular disorders warrant particular caution.
In the upper facial lines studies the adverse event profile was modest: injection site bruising in 2% of patients versus 1% on placebo, brow ptosis in 0.7%, and injection site discomfort in 0.6%. Eyelid ptosis remains the complication most likely to bring a patient back to your chair unhappy — our guide to droopy eyelid after Botox® covers recognition, management and prevention.
When a patient has stopped responding to another product
Because complexing proteins add to the protein load being injected, the theory has always been that a protein-free formulation should carry a lower risk of a patient developing neutralizing antibodies and losing response over time. The Xeomin® clinical program puts a number on it: across studies, 9 of roughly 3,000 patients (0.3%) were positive for neutralizing antibodies, with a further 4 (0.2%) developing them during treatment.
That is a low figure and a fair thing to discuss with a patient whose results have faded on another product. It is not a promise. Secondary non-response is multifactorial, the comparative rates between modern products are small, and no product is antibody-proof. The honest version is that a patient who has lost response elsewhere may reasonably be trialled on Xeomin® — not that Xeomin® cannot provoke antibodies.
The Other Neurotoxin Options
Six botulinum toxin type A products currently hold FDA approval for aesthetic use in the United States: Botox® Cosmetic, Dysport®, Xeomin®, Jeuveau®, Daxxify® and Letybo®, the newest, which was approved in February 2024 and launched in the U.S. in 2025. Five of the six are approved for glabellar lines only, which is what makes Xeomin®'s three-area approval and Botox®'s four-area approval stand out.
Two more are approved abroad and held at the FDA on manufacturing grounds rather than safety or efficacy: Allergan's Boey® (trenibotulinumtoxinE), a type E toxin with onset from about 8 hours and a duration of roughly two to three weeks, approved in Europe on July 17, 2026 and in Canada; and Galderma's Relfydess® (relabotulinumtoxinA), the first ready-to-use liquid toxin, approved in 33 markets. Each received a complete response letter in 2026 tied to manufacturing and analytical observations, with no deficiencies raised on the safety or efficacy sections of either application.
Free Online Botox® Training · Earn 1 CME Try Botox® training free.
Earn 1 CME on us.
Get self-paced access to a real IAPAM Botox® module — watch step-by-step injection technique, follow along with our physician instructors, and claim 1 AMA PRA Category 1 CME when you finish.
What’s Inside Your Free Module
Crow’s Feet Treatment TechniqueStep-by-step video
Facial Anatomy & Injection SitesHD video
Patient Consultation & SafetyBest practices
1 AMA PRA Cat 1 CMEOn completion
Full Module Value$79 — Free
Eligibility: MD/DO, NP, APRN/CRNA, PA, DMD/DDS, RN
Alternatives to Botox® That Are Not a Neurotoxin
Patients who ask for "something other than Botox®" often mean something other than a neurotoxin entirely. It is worth being clear with them that these options treat a different problem rather than the same problem a different way.
Hyaluronic acid fillers such as Juvéderm® and Restylane® address static lines, folds and volume loss. They contain no botulinum toxin of any kind — a point worth stressing, because a surprising amount of consumer material still lists Restylane® alongside the toxins as though it were one. Fillers add or restore volume; they do not relax muscle.
Energy-based devices — radiofrequency microneedling, microfocused ultrasound, and ablative and non-ablative resurfacing lasers — improve skin quality, texture and static lines, and some tighten tissue. They work on the skin envelope rather than the muscle beneath it.
Prescription retinoids and medical-grade skincare improve fine lines and photodamage over months of consistent use. They are a maintenance layer, not a substitute.
The honest summary for a patient: nothing in this list reproduces what a neurotoxin does. A dynamic line created by muscle contraction is treated by relaxing that muscle; everything else here addresses what has happened to the skin as a result. In practice, the best outcomes usually combine them — and knowing when to reach for which is a large part of what separates a confident consultation from a hopeful one.
Working Xeomin® Into a Practice
Product choice sits inside your scope of practice, which varies by state and by credential — if that is the open question, start with whether nurse practitioners can inject Botox®. Beyond scope, the practical considerations are inventory (room-temperature storage simplifies a satellite room or a mobile practice), the vial size that matches your booked volume, and whether your patient population includes people who have plateaued on another product.
For structured, product-specific instruction, IAPAM runs Xeomin® training for physicians alongside its core injectables curriculum.
Frequently Asked Questions
Can Xeomin® replace Botox® for the same treatment areas?
For the upper face, yes. Xeomin® is FDA-approved for moderate to severe glabellar lines, horizontal forehead lines and lateral canthal lines, which covers the areas most Botox® Cosmetic patients are treated for. Botox® additionally holds an approval for platysma bands that Xeomin® does not. Dosing is planned from the Xeomin® label rather than converted from another product.
Is Xeomin® approved for crow's feet and forehead lines?
Yes. On July 23, 2024 the FDA approved Xeomin® for moderate to severe lateral canthal lines and horizontal forehead lines in addition to glabellar lines, and it is the first and only U.S. neurotoxin approved for treating all three upper facial areas in the same session. The maximum recommended dose when all three areas are treated simultaneously is 64 Units. Older articles that describe crow's feet and forehead treatment with Xeomin® as off-label predate this approval.
How soon does Xeomin® work and how long does it last?
The median onset of treatment effect occurs within two to seven days of injection. The label directs that treatment be repeated no more frequently than every three months. Claims of five or six months of duration are not supported by the Xeomin® label. Individual results vary with dose, treated area, muscle mass and how strongly the patient animates.
What are the contraindications to Xeomin®?
The label lists exactly two: known hypersensitivity to botulinum neurotoxin type A or to any of the excipients, and infection at the proposed injection site. Separately, Xeomin® carries a boxed warning for distant spread of toxin effect, and warnings and precautions covering dysphagia and breathing difficulties, corneal exposure and ulceration, risk of ptosis in glabellar treatment, hypersensitivity reactions, and the human albumin excipient. Patients with neuromuscular disorders warrant particular caution.
Can Xeomin® be used during pregnancy?
Pregnancy is not listed as a contraindication, but it is not a green light either. The label states that Xeomin® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, after animal studies showed embryotoxicity in rats and increased abortions in rabbits at doses above the maximum recommended human dose. There are no data on Xeomin® in human milk. In aesthetic practice the usual position is to defer elective treatment.
What non-toxin alternatives to Botox® are there?
Hyaluronic acid fillers such as Juvéderm® and Restylane® treat static lines and volume loss and contain no botulinum toxin at all. Energy-based devices including radiofrequency microneedling, microfocused ultrasound and resurfacing lasers improve skin quality, texture and static lines. Prescription retinoids and medical-grade skincare improve fine lines over months of use. None of these reproduces neuromodulation of a dynamic line created by muscle contraction, so they complement a neurotoxin rather than replace it.
Training That Covers the Whole Toxin Category
Knowing which product to reach for is only useful alongside the anatomy, dosing judgment and consultation skill that make the result look natural. IAPAM has trained providers for 20 years in a clinical setting in Scottsdale, Arizona, with board-certified dermatologist instructors, live-model injection practice and AMA PRA Category 1 CME — and a 4.9-star rating across more than 6,300 documented reviews.
Explore IAPAM's hands-on Botox® training →
Not ready for a symposium seat? The free module above earns you 1 CME and shows you exactly how our instructors teach injection technique, at no cost.
Disclaimer: This guide is for informational and educational purposes only and does not constitute medical advice. Treatment plans, injection techniques, and dosing must be tailored to each patient by a qualified, licensed provider. Always follow product labeling, your scope of practice, and your state medical and nursing board regulations. Botox® is a registered trademark of Allergan, Inc.; Xeomin® is a registered trademark of Merz Pharma; Dysport® of Ipsen Biopharm; Jeuveau® of Evolus, Inc.; Daxxify® of Revance Therapeutics; Letybo® of Hugel, Inc.
